How I treat patients with myelodysplastic syndromes

Blood

Volumn 113, Issue 25, 2009, Pages 6296-6303

  Stone, Richard M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CLOFARABINE; CLORETAZINE; CYCLOSPORIN A; CYTARABINE; DEFERASIROX; DEFEROXAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; JANUS KINASE 2; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN C JUN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; ROMIPLOSTIM; THYMOCYTE ANTIBODY; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOPOIETIC GROWTH FACTOR; IRON CHELATING AGENT; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CATARACT; CHROMOSOME 5Q; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE INFLAMMATION; INJECTION SITE IRRITATION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON OVERLOAD; KARYOTYPE; LEUKOCYTE COUNT; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; AGED; ALLOTRANSPLANTATION; CHELATION THERAPY; CHROMOSOME 5; CHROMOSOME DELETION; CLINICAL TRIAL; DISEASE COURSE; DNA METHYLATION; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; MYELOID LEUKEMIA; REVIEW; ULTRASTRUCTURE;

ACUTE DISEASE; AGED; AZACITIDINE; CHELATION THERAPY; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DNA METHYLATION; ERYTHROPOIETIN; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON CHELATING AGENTS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TRANSPLANTATION, HOMOLOGOUS;

EID: 67650642121     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-038935     Document Type: Article

References (72)

1. Steensma DP. Are myelodysplastic syndromes "cancer?" Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006;30:1227-1233.
2. Nimer SD. Myelodsyplastic syndromes. Blood. 2008;111:4841-4851.
3. Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol. 2006;24:2576-2582. (Pubitemid 46630637)
4. Wang SA, Hasserjian RP, Lowe JM, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlappig myeloproliferative and myelodysplastic features. Leukemia. 2006;20: 1641-1644. (Pubitemid 44264118)
5. Emanuel P. Mixed myeloproliferative and myelodysplastic syndrome. Curr Hem Malig Rep. 2007; 2:9-12.
6. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43-52. (Pubitemid 36759634)
7. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17: 3128-3135. (Pubitemid 29470642)
8. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385-4395.
9. Bennett J, Catovsky D, Daniel MT. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100: 2292-2302.
11. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969-2977.
12. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: 2079-2088. (Pubitemid 27132124)
13. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503-3510. (Pubitemid 47315575)
14. Apperly JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487. (Pubitemid 34879335)
15. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature. 2008;451:335-339.
16. Greenberg PL, Attar E, Battiwalla M, et al. Myelodysplastic syndrome. J Natl Compr Canc Netw. 2008;6:902-906.
17. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603. (Pubitemid 46291823)
18. Cheson BD, Greenberg PL, Bennet JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108:419-425.
19. Negrin RS, Haeuber DB, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 1990;76: 36-43. (Pubitemid 20220788)
20. Herrman F, Lindemann A, Klein H, Lubbert M, Schulz G, Mertelsmann R. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia. 1989;3:335-338. (Pubitemid 19127555)
21. Anderson JE, Appelbaum F, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996; 87:51-58. (Pubitemid 26011819)
22. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100: 1997-2004. (Pubitemid 35001229)
23. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104:579-585. (Pubitemid 38900045)
24. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 2008;112:895-902.
25. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005; 105:1810-1814. (Pubitemid 40223707)
26. Field T, Perkins J, Alsina M, et al. Pre-transplant 5-azacitidine (Vidaza) may improve outcome of allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) [abstract]. Blood. 2006;108:1047a. Abstract 3664.
27. Stein RS. The role of erythropoietin in the anemia of myelodysplastic syndrome. Clin Lymphoma. 2003;4[Suppl 1]:S36-S40. (Pubitemid 37265933)
28. Park S, Grabar S, Kelaidi C, et al. Predictive factors or response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111:574-582.
29. Giraldo P, Nomdedu B, Loscertales J, et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer. 2006;107:2807-2816. (Pubitemid 44937034)
30. Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol. 2005;16: 1921-1927. (Pubitemid 41724281)
31. Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol. 2002;68: 180-185. (Pubitemid 34620608)
32. Rizzo JD, Somerfield M, Hagerty K, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008;111:25-41.
33. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104: 321-327. (Pubitemid 38900010)
34. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037-1046. (Pubitemid 36411563)
35. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008; 26:3607-3613.
36. Kantarjian H, Fenaux P, Sekeres M, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients with low-risk myelodysplastic syndrome: update including extended treatment [abstract]. Blood. 2007;110:81a. Abstract 250.
37. Kantarjian H, Giles F, Greenberg P, et al. Effect of romiplostim in patients with low or intermediate risk myelodysplastic syndrome receiving azacitidine [abstract]. Blood. 2008;112:89. Abstract 224.
38. Bussel J, Kuter D, George J, et al. AMG 531, a thrombopoiesis-stimulating protein for chronic ITP. N Engl J Med. 2006;355:2054.
39. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632-4639. (Pubitemid 36857840)
40. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia hightlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78:487-494. (Pubitemid 46753591)
41. Armand P, Kim H, Cutler C, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586-4588. (Pubitemid 46743431)
42. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597-1602. (Pubitemid 36578996)
43. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168-176.
44. Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw. 2006;4:91-96.
45. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465. (Pubitemid 44511560)
46. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86-93.
47. Sekeres M, Maciejewski J, Giagounidis AN, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26:5943-5949.
48. European Medicines Agency. Questions and Answers on Recommendations for the refusal of the marketing authorization for Lenalidomide Celgene Europe. www.emea.europa.eu/pdfs/human/opinion/Lenalidomide-27128808en.pdf. Accessed May 30, 2008.
49. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100: 304-309. (Pubitemid 28131061)
50. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699-705. (Pubitemid 27519877)
51. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102: 3025-3027. (Pubitemid 37248879)
52. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological response to anti-thymocyte globulin. Leukemia. 2007;21:1436-1441. (Pubitemid 46965284)
53. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
54. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903.
55. Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20: 2441-2452.
56. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndrome. J Clin Oncol. 27:1850-1856.
57. Fenaux P, Mufti G, Hellstrom-Lindberg E. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, openlabel phase III study. Lancet Oncol. 2009;10:223-232.
58. List AF, Fenaux P, Mufti GJ, et al. Effect of azacitidine on overall survival in higher-risk MDS without complete remission. J Clin Oncol. 2008;26: 373.
59. Grovdal, Khan R, Aggerholm A, et al. Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome or acute myeloid leukemia following MDS in complete remission after induction chemotherapy. Blood. 2008;112:89.
60. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794.
61. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS: the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol. 2005; 84[Suppl 13]:9-17. (Pubitemid 44419734)
62. Wijermans PW, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS study groups. Blood. 2008;112:90.
63. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57. (Pubitemid 46053042)
64. Steensma DP, Baer MR, Slack JL, et al. Preliminary results of a phase II study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndrome. Blood. 2007;110:1450.
65. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379-2386. (Pubitemid 37193573)
66. Giles F, Thomas D, Garcia-Manero G, et al. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res. 2004;10:2908-2917. (Pubitemid 38619664)
67. Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol. 2005;23:3957-3970.
68. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361-6369.
69. List A, Estes M, Williams A, et al. Lenalidomide (CC-5013;Revlimid) promotes erythropoiesis in myelodysplastic syndromes (MDS) by CD45 protein tyrosine phosphatase (PTP) inhibition. Blood. 2006;108:397a.
70. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004; 22:1287-1292. (Pubitemid 41079843)
71. Raza A, Callander N, Ochoa L, et al. Hematologic improvement (HI) by TLK199 (Telintra), a novel glutathione analog, in myelodysplastic syndrome: phase 2 study results. Blood. 2005;106:708a.
72. Sokol L, Cripe L, Kantarjian H, et al. Phase I/II, randomized multicenter, dose-ascension study of the p38MAPK inhibitor Scio-469 in patients with myelodysplastic syndrome (MDS) [abstract]. Blood. 2006;108:751a.